|
|
|
|
| LEADER |
01685nam a2200229 u 4500 |
| 001 |
EB002180520 |
| 003 |
EBX01000000000000001318007 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
231009 r ||| eng |
| 020 |
|
|
|a 9789240061996
|
| 020 |
|
|
|a 9789240061989
|
| 245 |
0 |
0 |
|a Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)
|h Elektronische Ressource
|
| 260 |
|
|
|a Geneva
|b World Health Organization
|c [2023], 2023
|
| 300 |
|
|
|a 1 PDF file (41 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a World Health Organization
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK590574
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Thrombotic Thrombocytopenia Syndrome (TTS) has emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines (AstraZeneca COVID-19 ChAdOx-1 vaccine and Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccine). TTS is a serious and life-threatening adverse event. WHO has issued this interim emergency guidance to increase awareness about TTS in the context of COVID-19 vaccination and help healthcare providers in the assessment and management of potential TTS cases. Knowledge about TTS following vaccination with a COVID-19 adenovirus vector-based vaccine is rapidly evolving. WHO will continue to monitor the situation closely for any changes that may affect this interim guidance and will update the guidance as needed
|